Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBITDA (2016 - 2025)

Neurocrine Biosciences' EBITDA history spans 16 years, with the latest figure at $153.6 million for Q4 2025.

  • For Q4 2025, EBITDA rose 62.71% year-over-year to $153.6 million; the TTM value through Dec 2025 reached $485.9 million, up 42.87%, while the annual FY2025 figure was $485.9 million, 42.87% up from the prior year.
  • EBITDA reached $153.6 million in Q4 2025 per NBIX's latest filing, down from $210.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $210.2 million in Q3 2025 to a low of -$71.4 million in Q1 2023.
  • Average EBITDA over 5 years is $66.2 million, with a median of $65.4 million recorded in 2022.
  • Peak YoY movement for EBITDA: surged 1111.7% in 2022, then plummeted 1233.33% in 2023.
  • A 5-year view of EBITDA shows it stood at -$9.4 million in 2021, then soared by 1111.7% to $95.1 million in 2022, then surged by 64.46% to $156.4 million in 2023, then plummeted by 39.64% to $94.4 million in 2024, then surged by 62.71% to $153.6 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's EBITDA are $153.6 million (Q4 2025), $210.2 million (Q3 2025), and $111.0 million (Q2 2025).